Press release content from Accesswire. The AP news staff was not involved in its creation.
Proenkephalin (penKid(R)) Included in the ADQI Consensus Statements Publication as Functional Kidney Biomarker for the Management of AKI Patients
December 16, 2020 GMT
The latest consensus meeting of international experts in critical care and nephrology supports the use of novel biomarkers in the prevention and management of Acute Kidney Injury (AKI)
The consensus recommends using a combination of damage and functional biomarkers together with clinical information for routine practice
Proenkephalin (penKid(R)), the kidney function biomarker, proposed as a marker for the assessment of AKI progression and kidney recovery
(1)
DGAP-News: SphingoTec GmbH / Key word(s): Scientific publication/Statement
Proenkephalin (penKid(R)) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients
16.12.2020 / 10:00
The issuer is solely responsible for the content of this announcement.
The latest consensus meeting of international experts in critical care and nephrology supports the use of novel biomarkers in the prevention and management of Acute Kidney Injury (AKI)
The consensus recommends using a combination of damage and functional biomarkers together with clinical information for routine practice
Proenkephalin (penKid(R)), the kidney function biomarker, proposed as a marker for the assessment of AKI progression and kidney recovery
Proenkephalin (penKid®) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients
The latest consensus meeting of international experts in critical care and nephrology supports the use of novel biomarkers in the prevention and management of Acute Kidney Injury (AKI)
The consensus recommends using a combination of damage and functional biomarkers together with clinical information for routine practice
Proenkephalin (penKid®), the kidney function biomarker, proposed as a marker for the assessment of AKI progression and kidney recovery
The CE-IVD marked assay for penKid® is available for point of care usage on the fully automated Nexus IB10 platform